Publications by authors named "Antonio Atanes-Sandoval"
The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the effectiveness of TNF inhibitors (adalimumab and infliximab) versus tocilizumab in treating refractory cystoid macular edema associated with Behçet’s disease.
- A multicenter analysis included 49 patients with cystoid macular edema who had already undergone other treatments; they were tracked for changes in macular thickness, visual acuity, and inflammation over four years.
- Results showed that all treatment options led to improvements in macular thickness and visual acuity, with tocilizumab still being effective for patients who did not respond to TNF inhibitors.
Objective: To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD).
Methods: We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement.